Delving into the Latest Updates on LY102 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis B, Chronic

Inactive Indication-

Originator Organization

Qingdao Haiji Biomedical Co., Ltd.

Active Organization

Qingdao Haiji Biomedical Co., Ltd.Qingdao Institute of Marine Biomedicine

Ocean University of China

Inactive Organization-

Drug Highest PhaseIND Approval

First Approval Date-

Regulation-

Login to view timeline

Pepsin from pigs was inhibited by 2 poly-L-lysines, LY 102 (mol. weight 12,300, d.p. 59) and LY 115 (mol. weight 43,870, d.p. 210), inhibition increasing over 3 hr, particularly with the latter.Maximum inhibitory concentrations of LY 102 and LY 115 were 70 and 40 μg/ml, resp.Both polylysines followed similar concentration-inhibition patterns, although the higher-mol.-weight substance appeared twice as active on a weight basis, probably indicating an easier access to a large number of interacting sites on the 2 macromols., pepsin and polylysine.Maximum optical absorbances (400 nm) did not usually occur at the same time as maximum inhibition; indee, for the highest inhibitions by both polylysines, the maximum absorbances occurred within 40 min after mixing pepsin and polylysine, while maximum inhibition occurred after ∼180 min.Highest inhibition therefore appears to be associated with the most rapid rate of formation of insoluble complex.The interaction between pepsin and these polylysines is apparently not completed instantaneously, and some aspect of the interaction proceeds with time, involving the active sites on the pepsin mol.

100 Deals associated with LY102

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B, Chronic	IND Approval	CN	Qingdao Institute of Marine Biomedicine	28 Mar 2024
Hepatitis B, Chronic	IND Approval	CN	Ocean University of China	28 Mar 2024
Hepatitis B, Chronic	IND Approval	CN	Qingdao Haiji Biomedical Co., Ltd.	28 Mar 2024